Unknown

Dataset Information

0

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

ABSTRACT:

SUBMITTER: Oberle A 

PROVIDER: S-EPMC5685239 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
| S-EPMC6169590 | biostudies-literature
Unknown Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
| S-EPMC7017193 | biostudies-literature
Unknown Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
| S-EPMC8475634 | biostudies-literature
Unknown Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
| S-EPMC4957162 | biostudies-literature
Unknown Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
| S-EPMC11976258 | biostudies-literature
Unknown Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.
| S-EPMC8234557 | biostudies-literature
Unknown Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
| S-EPMC4929758 | biostudies-literature
Unknown DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
| S-EPMC7214267 | biostudies-literature
Unknown Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
| S-EPMC5951903 | biostudies-literature
Unknown Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
| S-EPMC5732844 | biostudies-literature